#China #Shanghai #Drug Development #Eli Lilly #Abbisko Therapeutics

Abbisko Therapeutics and Eli Lilly: A Strategic Collaboration

Abbisko Therapeutics Co., Ltd., a prominent biopharmaceutical entity based in Shanghai, has announced a groundbreaking partnership with Eli Lilly and Company, a leading global pharmaceutical firm. This strategic collaboration aims to deepen their research and development efforts in creating new and innovative medicines targeting a variety of diseases. The partnership promises to harness the strengths of both companies in drug discovery and development, signaling a significant advancement in their mutual pursuit of therapeutic innovation.

Overview of the Collaboration

The agreement between Abbisko Therapeutics and Lilly will involve collaborative efforts in discovering and developing new drug candidates that possess global potential. By combining Abbisko’s expertise in early-stage drug discovery and Lilly’s extensive experience in global drug development, the two companies are set to accelerate the pace of bringing innovative therapeutic solutions to patients worldwide.

As outlined in the strategic agreement, Abbisko will deploy its well-established drug discovery platform and innovative research and development ecosystem. This will include conducting discovery and early phase development activities focusing on disease targets that Lilly selects. Abbisko stands to benefit significantly from this partnership as it will not only receive an upfront payment but also be eligible for milestones related to development, regulatory advancements, and commercial achievements, potentially amounting to around $1.9 billion.

Furthermore, Abbisko will receive tiered royalties based on the annual net sales of products derived from this collaboration, ensuring financial incentives are tightly aligned with the success of the new drug candidates.

Previous Partnership Milestones

This new agreement builds on the previous successful collaboration established in 2022, where Abbisko and Lilly had entered a global collaboration and exclusive license agreement to facilitate the discovery and development of a novel small-molecule therapeutic. The ongoing partnership illustrates Abbisko's commitment to fostering relationships that broaden its innovative capabilities while addressing unmet medical needs both domestically in China and on a global scale.

Abbisko’s Expanding Global Presence

Founded in April 2016, Abbisko Therapeutics has rapidly evolved into an oncology-centered biopharmaceutical company, concentrating on the discovery and development of unique therapies aimed at precision oncology and immuno-oncology. With a team comprised of seasoned professionals equipped with extensive research and development experience from top multinational pharmaceutical firms, Abbisko has cultivated a robust pipeline of innovative drugs designed to meet critical medical needs.

The collaboration with Eli Lilly is expected to further enhance Abbisko’s strategy by adding multiple innovative programs that strengthen its foothold in the global pharmaceutical landscape. The partnership also reflects Abbisko's ongoing commitment to advancing scientific innovation into tangible therapeutic advancements, ultimately benefitting patients who await new treatment options.

Conclusion

The partnership between Abbisko Therapeutics and Eli Lilly is poised to pave the way for significant advancements in drug discovery and development. By leveraging each other's strengths, Abbisko and Lilly aim to introduce new treatments that can address critical health challenges faced by patients around the world. As research and development efforts continue, this collaboration stands as a testament to the ongoing evolution of pharmaceutical innovation in an increasingly globalized healthcare environment.

For more information on Abbisko Therapeutics, visit www.abbisko.com.